Comparison on Efficacy of S-1 Respectively Combined with Oxaliplatin and Docetaxel for Advanced Gastric Cancer

Abstract
Figure/Table
References (11)
Related Citation (15)

Download: PDF (306 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To compare the short-term efficacy and safety of S-1 respectively combined with oxaliplatin (OXA) and docetaxel (TXT) in treatment of advanced gastric cancer. Method: Forty-three patients with advanced gastric cancer were randomly divided into OXA group (n ＝ 26) and TXT group (n ＝ 17). Drug usage was as follows: oral administration of 40 mg/m2 S-1 during days 1 ～ 14, twice a day; intravenous injection of 130 mg/m2 OXA on day 1; intravenous injection of 60 mg/m2 TXT on day 1; 3 weeks as one cycle. The efficacy, adverse reactions and quality of life were evaluated 2 cycles after treatment. Results: Adverse reactions could be evaluated in all cases, and efficacy be evaluated in 42 cases. The response rates (RR) were 57.7% and 31.3% respectively in OXA and TXT groups, without statistical significance (P ＝ 0.096). The incidence of total leukopenia (100.0%), stomatitis (35.3%) and constipation (76.5%) was obviously higher in TXT group than in OXA group (50.0%, 3.8%, 38.4%), with statistical significance (P ＝ 0.019, 0.006, 0.015), while that of neurotoxicity lower than in OXA group (53.8% vs. 17.6%), with statistical significance (P ＝ 0.018). Conclusion: For advanced gastric cancer, S-1 combined with OXA is similar to efficacy of combined with TXT, but with less adverse reactions.

Corresponding Authors: Lu Jianwei, E-mail: lujw@medmail.com.cn

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhi Junna
	Wu Tingting
	Zhao Benhui
	Chen Dingding
	Lu Jianwei

Cite this article:

Zhi Junna,Wu Tingting,Zhao Benhui, et al. Comparison on Efficacy of S-1 Respectively Combined with Oxaliplatin and Docetaxel for Advanced Gastric Cancer[J]. Journal of International Translational Medicine, 2014, 2(1): 270-273.

URL:

http://www.jitm.hk/EN/ OR http://www.jitm.hk/EN/Y2014/V2/I1/270

1 Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
2 Wang G, Zhang JH. New advances of treatment in surgical department of gastric cancer. China Medical Herald 2009; 6: 11-3.
3 Jin M, Chen Q, Cheng FQ, et al. Study on oxaliplatin combined with calcium folinatc and 5- fluorouracil for advanced gastric cancer. Chinese Journal of Oncology 2003; 25: 172-4.
4 Chu QS-C, Hammond LA, Schwartz G, et al. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res 2004; 10: 4913-21.
5 Huang J, Cao Y, Wu L, et al. S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a metaanalysis. Med Oncol 2011; 28: 1004-11.
6 Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-21.
7 Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and metaanalysis. Gastric Cancer 2011; 14: 50-5.
8 Oh SY, Kwon H-C, Jeong S-H, et al. A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Invest New Drugs 2012; 30: 350-6.
9 Park I, Lee J-L, Ryu M-H, et al. Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. Cancer Chemother Pharmacol 2010; 65: 473-80.
10 Koizumi W, Kim YH, Fujii M, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastriccancer: a randomized study (START). J Cancer Res Clin Oncol 2014; 140: 319-28.
11 Yoshida K, Ninomiya M, Takakura N, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006; 12: 3402-7.